ViewsML

We’re appreciative of the Mayo Clinic's support as we work towards a collective goal to enable more efficient, scalable and data-informed pathology practices.    “This commitment reflects Mayo Clinic’s mission to thoughtfully integrate emerging technologies in ways that meaningfully improve patient care,” said Jim Rogers, CEO of Mayo Clinic Digital Pathology. “By advancing digital pathology capabilities, we are enabling our clinicians to deliver faster, more precise insights while also creating new opportunities for research and discovery.”   Read more in today’s press release: https://lnkd.in/gVfNUDac #DigitalPathology #VirtualBiomarkerStaining #VirtualBiomarkers #Pathology

Thank you to the Province of British Columbia for providing more than $5.3 million in grants to support testing of innovative health and life-sciences products from BC-based companies, which have the potential to revolutionize health care and achieve better health outcomes for patients.   We’re proud to be part of British Columbia’s health tech ecosystem and appreciative of the Province’s support as we advance faster, more consistent, and scalable biomarker detection. As Providence Health Care has one of the largest biobanks, it is nearly impossible to characterize biomarker expression manually due to wet lab and tissue constraints. Our AI-powered virtual staining technology predicts biomarker expression from a single digital H&E image in minutes, thereby generating commercial-ready datasets without consuming precious tissue samples.   Learn more from Innovate BC: https://lnkd.in/ew3uHi8x

The 12th Digital Pathology & AI Congress is this week. We're excited to be on the exhibition floor at The Ohio Union both days. This year's program spans AI integration in clinical workflows, spatial biology in drug development, and the real-world challenges of scaling digital pathology. As a company delivering AI-powered virtual staining and spatial biomarker insights directly from H&E slides, ViewsML is built for exactly these conversations. Come visit us and talk about what we're working on. Contact us for a meeting: https://lnkd.in/eh8mfdTm  #DigiPathUSA #DigitalPathology #ComputationalPathology

One of the central questions at this year's Digital Pathology & AI Congress: how does AI-powered pathology move from pilot to practice? It's a question ViewsML thinks about every day, and one we're looking forward to digging into in person. We'll be exhibiting from May 7–8. If you're attending, visit us to learn more about how we’re driving virtual staining of biomarkers from H&E slides, and where the field is headed. Contact us for a meeting: https://lnkd.in/eh8mfdTm  #DigitalPathology #AIPathology #SpatialBiology #DigiPathUSA

BetaKit covered our recent $4.9M CAD financing round, providing additional insights from our CEO, Kenneth To.     The round was led by Wittington Ventures, with new investors Continuum Health Ventures and Mayo Clinic, alongside repeat investors RiSC Capital, Debiopharm, WUTIF Capital, Defined, and eFund.     The funding will be used to accelerate commercialization of our AI-driven platform for virtual staining of biomarkers, expand strategic partnerships, advance clinical validation of our virtual biomarker panels, and grow our team in support of our mission to transform tissue analysis from a lab process into software.    Read more: https://lnkd.in/eg75ntyi    #SeedFunding #BiotechStartup #Biomarkers #DigitalPathology #VirtualStaining #VirtualBiomarkerStaining 

ViewsML is heading to Columbus for the 12th Digital Pathology & AI Congress and 3rd American Spatial Biology Congress from May 7–8 at The Ohio Union. This conference dives into the merging world of digital pathology and spatial biology. As a company delivering AI-powered virtual staining and spatial biomarker insights directly from H&E slides, we’re excited to be exhibiting and ready to connect with researchers, clinicians, and industry leaders pushing this space forward. We look forward to meeting you on the exhibition floor. Contact us for a meeting: https://lnkd.in/eh8mfdTm  #DigiPathUSA #DigitalPathology #ComputationalPathology

We are honored by the support of the lead investor of our latest financing round, Wittington Ventures -- as well as investors Continuum Health Ventures, Mayo Clinic, RiSC Capital, Debiopharm, WUTIF Capital, Defined and eFund!

ViewsML's Christopher Jackson, MD, MEng, Chief Scientific Officer, recently did a Q&A with The Pathologist about our approach to using AI to generate virtual staining of biomarkers from routine H&E slides. He also discussed our recent study to evaluate a virtual biomarker panel in non-small cell lung cancer (NSCLC) using markers representing tumor, stromal, vascular, and immune compartment biomarkers.   Read the article: https://lnkd.in/en-mZJNZ   #Pathology #DigitalPathology #VirtualStaining #VirtualBiomarkerStaining #AIinPathology #Biomarkers #CancerResearch 

ViewsML closes $4.9M seed to virtualize IHC staining 🧬 The traditional immunohistochemistry workflow takes days to weeks. ViewsML's platform extracts biomarker data from standard H&E slides in minutes. Wittington Ventures led the round with Continuum Health Ventures, Mayo Clinic, RiSC Capital, Debiopharm, WUTIF, Defined, and e-Fund participating. Here's the constraint they're solving: every physical IHC stain consumes irreplaceable tissue. When you're running 10+ biomarker panels in drug development, you burn through samples fast. This puts pressure on both pharma discovery timelines and diagnostic workflows where tissue is limited. Their platform generates per-cell spatial biomarker data computationally. No wet lab. No tissue consumption. The Vancouver team built what they're calling the world's first virtual biomarker library—an expanding set of AI models trained to predict biomarker expression from routine pathology. This matters because spatial biology is exploding in oncology and immunology research. Akoya Biosciences, Inc. and others have shown the value of multiplexed spatial data, but they still require physical tissue and complex protocols. Virtual staining sidesteps that entirely. The real test: regulatory validation for clinical use. Virtual biomarkers need to match physical IHC performance in prospective trials before they replace anything in diagnostics. How many virtual biomarkers need clinical validation before pathology labs start trusting computational predictions over physical stains? #DigitalPathology #ComputationalBiology #DrugDevelopment #AIinHealthcare

It has been a productive week so far at The American Association for Cancer Research® (AACR) Annual Meeting 2026! Thank you to everyone who stopped by our poster on Sunday. Be sure to visit the two poster sessions we're participating in with Debiopharm and HistoWiz happening now (4/21) until 12pm in Section 3. There's still time to come chat with us at booth #1557 about how our AI-powered virtual immunohistochemistry (vIHC) platform is transforming biomarker detection. #AACR26 #DigitalPathology #VirtualIHC #PrecisionMedicine #VirtualStaining #VirtualBiomarkerStaining